Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.
A scathing article in the New York Times on June 21, 2024 did an excellent service to Americans facing the highest price of drugs in the world. While the social media and the stakeholders blame drug companies, insurers, or a dysfunctional federal government, the real culprits are the 3 big pharmacy benefits managers (PBMs; CVS Health, Cigna, and UnitedHealth Group), hired by employers and governments. If they were stand-alone companies, the 3 biggest PBMs would each rank among the top 40 US companies by revenue. The largest, Caremark, generates more revenue than Ford or Home Depot.
Image credit: JOURNEY STUDIO7 - stock.adobe.com
PBMs have been around since the late 1950s. They initially handled requests mailed in by pharmacies and patients seeking reimbursement for the costs of prescription drugs. Over the decades, PBMs have had different owners, including drug makers and large chains of pharmacies. They were often credited with saving money for patients and employers, including in the early 2010s when they embraced a new wave of generic drugs. They kept a slice of the savings for themselves. The modern PBM emerged in 2018. The giant health insurers Aetna and Cigna were trying to achieve the growth demanded by Wall Street. They sought to merge with the PBMs, whose profits were soaring. Aetna and CVS combined. Cigna bought Express Scripts (UnitedHealth had built its PBM).
The job of the PBMs is supposedly to reduce drug costs. Instead, they frequently do the opposite. A New York State investigation found that they steer patients toward pricier drugs, charge steep markups on what would otherwise be inexpensive medicines, and extract billions of dollars in hidden fees, a New York State investigation found.
Most Americans get their health insurance through a government program like Medicare or through an employer, which pays for 2 different types of insurance for each person. One type covers visits to doctors and hospitals, handled by an insurance company. The other pays for prescriptions. That is overseen by a PBM who negotiates with drug companies, pays pharmacies, and helps decide which drugs patients can get at what price. In theory, everyone saves money. But the PBMs have excellent public relations campaigns: “We’re good at what we do,” Jon Mahrt, president of UnitedHealth’s PBM, Optum Rx, said in an interview. The leading lobbying group for the PBMs says that in 2022, they saved their clients and patients $286 billion. But those savings appear to be primarily a mirage, a product of a system where prices have been artificially inflated so that major PBMs and drug companies can boost their profits while taking credit for reducing prices. This is how the system works:
Many patients learn about the existence of PBMs only when they have a problem getting medications and spend hours navigating a byzantine system of approvals and restrictions. However, the PBMs’ business practices touch virtually every American family. Even people who don’t take prescription drugs end up paying higher insurance premiums and taxes because of inflated drug costs.
In Washington and state capitals, lawmakers, regulators, and attorneys have suggested that the benefit managers may be inflating drug prices and engaging in anticompetitive behavior.
The Senate bill S127—Pharmacy Benefit Manager Transparency Act of 2023 in 118th Congress (2023-2024—would generally prohibits PBMs from engaging in certain practices when managing prescription drug benefits under a health insurance plan, including charging the plan a different amount than the PBM reimburses the pharmacy. The bill also prohibits PBMs from arbitrarily, unfairly, or deceptively (1) clawing back reimbursement payments or (2) increasing fees or lowering reimbursements to pharmacies to offset changes to federally funded health plans. PBMs are not subject to these prohibitions if they (1) pass along 100% of any price concession or discount to the health plan and (2) disclose specified costs, prices, reimbursements, fees, markups, discounts, and aggregate payments received concerning their PBM services. Further, PBMs must report annually to the Federal Trade Commission (FTC) specific information about payments received from health plans and fees charged to pharmacies. The FTC and state attorneys general are authorized to enforce the bill's provisions.
It would turn out to be a seminal moment, one that would rapidly and radically change the American health care system by further shifting power into the hands of giant conglomerates and away from employers and patients, but dozens of such bills in Congress have come and sat there for years; the lobby of PBMs is indeed influential and why not when they have the resources to lobby. Only the US Congress can do something to alleviate the cost of drugs.
Biosimilars are supposed to reduce the cost to patients substantially, but so far, the prices for biosimilars are typically 15% to 35% lower than their respective brand-name reference biologic. One of the causes of this minor change is the role of PBMs. What good are the biosimilars if the PBM maintains them unaffordable?
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Celltrion, Costco Partnership; Amgen Sues Samsung Bioepis; Denosumab Results
August 21st 2024Celltrion's adalimumab-aaty biosimilar is now accessible for all Costco members, while Amgen sues Samsung Bioepis over the latter’s denosumab biosimilar candidate, and GlycoNex progresses its denosumab biosimilar SPD8 to phase 3 trials.
CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel
August 19th 2024CMS announced negotiated prices for 10 drugs under the Inflation Reduction Act (IRA), sparking mixed reactions, with concerns that including drugs facing imminent biosimilar competition could hinder market access to lower-cost alternatives.